UBS Group AG Has $6.28 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

UBS Group AG increased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report) by 151.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 290,801 shares of the company’s stock after acquiring an additional 175,244 shares during the period. UBS Group AG owned about 0.34% of Syndax Pharmaceuticals worth $6,284,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. CWM LLC raised its holdings in shares of Syndax Pharmaceuticals by 415.3% in the 4th quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after acquiring an additional 1,358 shares during the last quarter. MeadowBrook Investment Advisors LLC purchased a new stake in Syndax Pharmaceuticals in the 4th quarter valued at about $37,000. Quadrant Capital Group LLC increased its stake in Syndax Pharmaceuticals by 158.3% in the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after buying an additional 1,496 shares during the last quarter. Signaturefd LLC increased its stake in Syndax Pharmaceuticals by 2,874.6% in the 4th quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock valued at $81,000 after buying an additional 3,622 shares during the last quarter. Finally, Annandale Capital LLC purchased a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at about $67,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup decreased their price objective on shares of Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $34.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 21st. HC Wainwright reiterated a “buy” rating and issued a $41.00 price objective on shares of Syndax Pharmaceuticals in a research note on Thursday. Finally, Stifel Nicolaus increased their price objective on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.42.

Get Our Latest Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Trading Up 1.0 %

SNDX opened at $19.40 on Friday. The company has a 50 day moving average of $21.29 and a 200 day moving average of $21.08. The company has a market cap of $1.65 billion, a PE ratio of -6.02 and a beta of 1.01. Syndax Pharmaceuticals, Inc. has a 12 month low of $11.22 and a 12 month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.11. During the same quarter in the prior year, the company earned ($0.59) earnings per share. Research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.57 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Featured Stories

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.